Research progress on the mechanism of endocrine therapy resistance for breast cancer

Abstract

Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356.

References43

[1]	Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial[J]. Lancet Oncol, 2010, 11(12): 1135-1141. DOI: 10.1016/S1470-2045(10)70257-6. doi:10.1016/S1470-2045(10)70257-6pmid:21087898
[2]	Clatot F, Perdrix A, Beaussire L, et al. Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer[J]. Breast Cancer Research, 2020, 22(1): 56. DOI: 10.1186/s13058-020-01290-x. doi:10.1186/s13058-020-01290-xpmid:32466779
[3]	Jeselsohn R, Bergholz JS, Pun M, et al. Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations[J]. Cancer Cell, 2018, 33(2): 173-186. e5. DOI: 10.1016/j.ccell.2018.01.004. doi:S1535-6108(18)30004-7pmid:29438694
[4]	Hartmaier RJ, Trabucco SE, Priedigkeit N, et al. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer[J]. Ann Oncol, 2018, 29(4): 872-880. DOI: 10.1093/annonc/mdy025. doi:S0923-7534(19)45471-9pmid:29360925
[5]	Li L, Lin L, Veeraraghavan J, et al. Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance[J]. Breast Cancer Res, 2020, 22(1): 84. DOI: 10.1186/s13058-020-01325-3. doi:10.1186/s13058-020-01325-3pmid:32771039
[6]	Sun G, Wang C, Wang S, et al. An H3K4me3 reader, BAP18 as an adaptor of COMPASS-like core subunits co-activates ERα action and associates with the sensitivity of antiestrogen in breast cancer[J]. Nucleic Acids Res, 2020, 48(19): 10768-10784. DOI: 10.1093/nar/gkaa787. doi:10.1093/nar/gkaa787pmid:32986841
[7]	Achinger-Kawecka J, Valdes-Mora F, Luu PL, et al. Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer[J]. Nat Commun, 2020, 11(1): 320. DOI: 10.1038/s41467-019-14098-x. doi:10.1038/s41467-019-14098-xpmid:31949157
[8]	Nassa G, Salvati A, Tarallo R, et al. Inhibition of histone methyltransferase DOT1L silences ERα gene and blocks proliferation of antiestrogen-resistant breast cancer cells[J]. Sci Adv, 2019, 5(2): eaav5590. DOI: 10.1126/sciadv.aav5590. doi:10.1126/sciadv.aav5590
[9]	Linares A, Assou S, Lapierre M, et al. Increased expression of the HDAC9 gene is associated with antiestrogen resistance of breast cancers[J]. Mol Oncol, 2019, 13(7): 1534-1547. DOI: 10.1002/1878-0261.12505. doi:10.1002/1878-0261.12505pmid:31099456
[10]	Yu S, Gong X, Ma Z, et al. Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage[J]. Cell Oncol (Dordr), 2020, 43(1): 65-80. DOI: 10.1007/s13402-019-00439-x. doi:10.1007/s13402-019-00439-x
[11]	Jiang Z, Li W, Hu X, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(6): 806-815. DOI: 10.1016/S1470-2045(19)30164-0. doi:S1470-2045(19)30164-0pmid:31036468
[12]	Peng WX, Koirala P, Zhou H, et al. Lnc-DC promotes estrogen Independent growth and tamoxifen resistance in breast cancer[J]. Cell Death Dis, 2021, 12(11): 1000. DOI: 10.1038/s41419-021-04288-1. doi:10.1038/s41419-021-04288-1
[13]	Feng J, Wen T, Li Z, et al. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/CDK2 axis promotes progression of ER⁺breast cancer and confers tamoxifen resistance[J]. Aging (Albany NY), 2020, 12(20): 20658-20683. DOI: 10.18632/aging.103966. doi:10.18632/aging.103966
[14]	Li J, Lu M, Jin J, et al. miR-449a suppresses tamoxifen resistance in human breast cancer cells by targeting ADAM22[J]. Cell Physiol Biochem, 2018, 50(1): 136-149. DOI: 10.1159/000493964. doi:10.1159/000493964pmid:30278449
[15]	Croessmann S, Formisano L, Kinch LN, et al. Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER⁺/HER2 mutant breast cancer[J]. Clin Cancer Res, 2019, 25(1): 277-289. DOI: 10.1158/1078-0432.CCR-18-1544. doi:10.1158/1078-0432.CCR-18-1544pmid:30314968
[16]	Ribas R, Pancholi S, Rani A, et al. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer[J]. Breast Cancer Res, 2018, 20(1): 44. DOI: 10.1186/s13058-018-0983-1. doi:10.1186/s13058-018-0983-1pmid:29880014
[17]	Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20. DOI: 10.1056/NEJMoa2203690. doi:10.1056/NEJMoa2203690
[18]	Choi HJ, Joo HS, Won HY, et al. Role of RBP2-induced ER and IGF1R-ErbB signaling in tamoxifen resistance in breast cancer[J]. J Natl Cancer Inst, 2018, 110(4): 400-410. DOI: 10.1093/jnci/djx207. doi:10.1093/jnci/djx207
[19]	Nagle AM, Levine KM, Tasdemir N, et al. Loss of E-cadherin enhances IGF1-IGF1R pathway activation and sensitizes breast cancers to anti-IGF1R/InsR inhibitors[J]. Clin Cancer Res, 2018, 24(20): 5165-5177. DOI: 10.1158/1078-0432.CCR-18-0279. doi:10.1158/1078-0432.CCR-18-0279pmid:29941485
[20]	Drago JZ, Formisano L, Juric D, et al. FGFR1 amplification me-diates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor-positive (HR⁺) breast cancer[J]. Clin Cancer Res, 2019, 25(21): 6443-6451. DOI: 10.1158/1078-0432.CCR-19-0138. doi:10.1158/1078-0432.CCR-19-0138
[21]	Walsh L, Haley KE, Moran B, et al. BET inhibition as a rational therapeutic strategy for invasive lobular breast cancer[J]. Clin Cancer Res, 2019, 25(23): 7139-7150. DOI: 10.1158/1078-0432.CCR-19-0713. doi:10.1158/1078-0432.CCR-19-0713pmid:31409615
[22]	Jacquemetton J, Kassem L, Poulard C, et al. Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant[J]. Breast Cancer Res, 2021, 23(1): 57. DOI: 10.1186/s13058-021-01433-8. doi:10.1186/s13058-021-01433-8pmid:34020697
[23]	André F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1[J]. Ann Oncol, 2021, 32(2): 208-217. DOI: 10.1016/j.annonc.2020.11.011. doi:10.1016/j.annonc.2020.11.011pmid:33246021
[24]	Dent S, Cortés J, Im YH, et al. Phase Ⅲ randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial[J]. Ann Oncol, 2021, 32(2): 197-207. DOI: 10.1016/j.annonc.2020.10.596. doi:10.1016/j.annonc.2020.10.596pmid:33186740
[25]	Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target[J]. Oncotarget, 2018, 9(48): 28989-29006. DOI: 10.18632/oncotarget.25615. doi:10.18632/oncotarget.25615pmid:29989029
[26]	Vidula N, Yau C, Rugo H. Trophoblast cell surface antigen 2 gene (TACSTD2) expression in primary breast cancer[J]. Breast Cancer Res Treat, 2022, 194(3): 569-575. DOI: 10.1007/s10549-022-06660-x. doi:10.1007/s10549-022-06660-x
[27]	Rugo HS, Bardia A, Marmé F, et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer[J]. J Clin Oncol, 2022, 40(29): 3365-3376. DOI: 10.1200/JCO.22.01002. doi:10.1200/JCO.22.01002
[28]	Pancholi S, Ribas R, Simigdala N, et al. Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities[J]. Oncogene, 2020, 39(25): 4781-4797. DOI: 10.1038/s41388-020-1284-6. doi:10.1038/s41388-020-1284-6pmid:32307447
[29]	Kettner NM, Vijayaraghavan S, Durak MG, et al. Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer[J]. Clin Cancer Res, 2019, 25(13): 3996-4013. DOI: 10.1158/1078-0432.CCR-18-3274. doi:10.1158/1078-0432.CCR-18-3274pmid:30867218
[30]	Alves CL, Ehmsen S, Terp MG, et al. Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer[J]. Nat Commun, 2021, 12(1): 5112. DOI: 10.1038/s41467-021-25422-9. doi:10.1038/s41467-021-25422-9pmid:34433817
[31]	Bardia A, Hurvitz SA, DeMichele A, et al. Phase Ⅰ/Ⅱ trial of exemestane, ribociclib, and everolimus in women with HR⁺/HER2^-advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1)[J]. Clin Cancer Res, 2021, 27(15): 4177-4185. DOI: 10.1158/1078-0432.CCR-20-2114. doi:10.1158/1078-0432.CCR-20-2114
[32]	Santiago-Gómez A, Kedward T, Simões BM, et al. PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer[J]. Cancer Lett, 2019, 458: 66-75. DOI: 10.1016/j.canlet.2019.05.014. doi:S0304-3835(19)30309-Xpmid:31121213
[33]	Simões BM, Santiago-Gómez A, Chiodo C, et al. Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer[J]. Oncogene, 2020, 39(25): 4896-4908. DOI: 10.1038/s41388-020-1335-z. doi:10.1038/s41388-020-1335-zpmid:32472077
[34]	Mavingire N, Campbell P, Wooten J, et al. Cancer stem cells: culprits in endocrine resistance and racial disparities in breast cancer outcomes[J]. Cancer Lett, 2021, 500: 64-74. DOI: 10.1016/j.canlet.2020.12.014. doi:10.1016/j.canlet.2020.12.014pmid:33309858
[35]	Piggott L, Silva A, Robinson T, et al. Acquired resistance of ER-positive breast cancer to endocrine treatment confers an adaptive sensitivity to TRAIL through posttranslational downregulation of c-FLIP[J]. Clin Cancer Res, 2018, 24(10): 2452-2463. DOI: 10.1158/1078-0432.CCR-17-1381. doi:10.1158/1078-0432.CCR-17-1381pmid:29363524
[36]	Bacci M, Lorito N, Ippolito L, et al. Reprogramming of amino acid transporters to support aspartate and glutamate dependency sustains endocrine resistance in breast cancer[J]. Cell Rep, 2019, 28(1): 104-118. e8. DOI: 10.1016/j.celrep.2019.06.010. doi:S2211-1247(19)30768-5pmid:31269432
[37]	He M, Jin Q, Chen C, et al. The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells[J]. Oncogene, 2019, 38(28): 5551-5565. DOI: 10.1038/s41388-019-0817-3. doi:10.1038/s41388-019-0817-3pmid:30967627
[38]	Gökmen-Polar Y, Neelamraju Y, Goswami CP, et al. Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways[J]. EMBO Rep, 2019, 20(2): e46078. DOI: 10.15252/embr.201846078. doi:10.15252/embr.201846078
[39]	Morotti M, Bridges E, Valli A, et al. Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer[J]. Proc Natl Acad Sci U S A, 2019, 116(25): 12452-12461. DOI: 10.1073/pnas.1818521116. doi:10.1073/pnas.1818521116
[40]	Joffroy CM, Buck MB, Stope MB, et al. Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer[J]. Cancer Res, 2010, 70(4): 1314-1322. DOI: 10.1158/0008-5472.CAN-09-3292. doi:10.1158/0008-5472.CAN-09-3292pmid:20145137
[41]	Anurag M, Zhu M, Huang C, et al. Immune checkpoint profiles in luminal B breast cancer (alliance)[J]. J Natl Cancer Inst, 2020, 112(7): 737-746. DOI: 10.1093/jnci/djz213. doi:10.1093/jnci/djz213pmid:31665365
[42]	Yang F, Xie HY, Yang LF, et al. Stabilization of MORC2 by estrogen and antiestrogens through GPER1-PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells[J]. Autophagy, 2020, 16(6): 1061-1076. DOI: 10.1080/15548627.2019.1659609. doi:10.1080/15548627.2019.1659609pmid:32401166
[43]	Actis C, Muzio G, Autelli R. Autophagy triggers tamoxifen resistance in human breast cancer cells by preventing drug-induced lysosomal damage[J]. Cancers (Basel), 2021, 13(6): 1252. DOI: 10.3390/cancers13061252. doi:10.3390/cancers13061252

Research progress on the mechanism of endocrine therapy resistance for breast cancer

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References43

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Gong Yan, Chen Honglei.Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer[J]. Journal of International Oncology, 2024, 51(3): 186-190.
[5]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[6]	Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer： present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58.
[7]	Wang Jing, Xu Wenting.Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526.
[8]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531.
[9]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456.
[10]	Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462.
[11]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui.Research progress of Nrf2 in ovarian cancer[J]. Journal of International Oncology, 2023, 50(8): 493-497.
[12]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[13]	Ding Hao, Ying Jintao, Fu Maoyong.Research progress of CAR-T in the treatment of esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(4): 231-235.
[14]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240.
[15]	Li Jiaxuan, Feng Yinglu.Mechanism of action of glucocorticoid receptors in the growth of hepatoma cells[J]. Journal of International Oncology, 2023, 50(4): 241-243.